SEARCH

SEARCH BY CITATION

References

  • 1
    Elton E & Hanauer SB. Review article: the medical management of Crohn’s disease. Aliment Pharmacol Ther 1996; 10: 1 22.
  • 2
    Greenberg GR, Feagan BG, Martin F, et al.Oral budesonide for active Crohn’s disease (Canadian Inflammatory Bowel Disease Study Group). N Engl J Med 1994; 331: 836 41.
  • 3
    Rutgeerts P, Löfberg R, Malchow H, et al.A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994; 331: 842 5.
  • 4
    Campieri M, Ferguson A, Doe W, International Budesonide Study Group. Oral budesonide competes favourably with prednisolone in active Crohn’s disease. Gut 1997; 41: 209 14.
  • 5
    Greenberg GR, Feagan BG, Martin F, et al.Oral budesonide as maintenance treatment for Crohn’s disease: A placebo-controlled, dose-ranging study (Canadian Inflammatory Bowel Disease Study Group). Gastroenterology 1996; 110: 45 51.
  • 6
    Löfberg R, Rutgeerts P, Malchow H, et al.Budesonide CIR for maintenance of remission in ileocecal Crohn’s disease. A European multicenter placebo controlled trial for 12 months. Gut 1996; 39: 82 6.
  • 7
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439 44.
  • 8
    Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249 66.
  • 9
    Begg C, Cho M, Eastwood S, et al.Improving the quality of reporting of randomized controlled trials. J Am Med Assoc 1996; 276: 8, 637 9.
  • 10
    Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn’s disease activity index, revealed by an objective gut lavage test of gastro-intestinal protein loss. Aliment Pharmacol Ther 1996; 10: 321 6.
  • 11
    Bayless TM. Maintenance therapy for Crohn’s disease. Editorial. Gastroenterology 1996; 110: 299 302.
  • 12
    O’donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978; 2: 955 7.
  • 13
    Thomson ABR, International Mesalazine Study Group. Coated oral 5-aminosalicylic acid vs. placebo in maintaining remission in Crohn’s disease. Aliment Pharmacol Ther 1990; 4: 55 64.
  • 14
    Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, The Italian Inflammatory Bowel Disease Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology 1992; 103: 363 8.
  • 15
    Ferguson A. Ulcerative colitis and Crohn’s disease—important and disabling diseases, still under-researched. Br Med J 1994; 39: 355 6.